Abstract
Background: We performed a randomized controlled chemoprevention trial of oral leukoplakia by administrating a low dose of beta-carotene and vitamin C supplements. 17% of subjects in the experimental arm (4/23) demonstrated clinical remission (complete or partial response) at completion of the trial. The objective of this study was to determine whether baseline expression of p53 and ki67 demonstrated any differences between those responding or not responding to our intervention. A secondary objective was to elucidate any relationship between dietary factors and clinical responses. Methods: For this biomarker study, we included all subjects in the experimental group (n = 23) who were non-smokers. Among 16 who completed the trial for 1 year of supplementation, there were four responders and 12 non-responders at 1-year follow-up. Following immuno-staining for p53 and ki67, the percentage of positive cell nuclei were analyzed as labeling index (LI). Results: Expression of p53 was greater in basal layers than in para-basal layers. Mean para-basal LI of p53 was higher in non-responding (26.0) than in responding subjects (11.2) (P = 0.028). ki67 LIs were not significantly different in the two groups. Conclusions: Expression of p53 was inversely related to clinical response to the supplements. Other biomarkers that may recognize subject's responsiveness to chemoprevention require further study.
| Original language | English |
|---|---|
| Pages (from-to) | 346-352 |
| Number of pages | 7 |
| Journal | Journal of Oral Pathology and Medicine |
| Volume | 46 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 05-2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Pathology and Forensic Medicine
- Oral Surgery
- Otorhinolaryngology
- Cancer Research
- Periodontics
Cite this
}
p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia. / Nagao, Toru; Warnakulasuriya, Saman; Sakuma, Hidenori; Miyabe, Satoru; Hasegawa, Shogo; Machida, Junichiro; Suzuki, Koji; Fukano, Hideo; Shimozato, Kazuo; Hashimoto, Shuji.
In: Journal of Oral Pathology and Medicine, Vol. 46, No. 5, 05.2017, p. 346-352.Research output: Contribution to journal › Article
TY - JOUR
T1 - p53 and ki67 as biomarkers in determining response to chemoprevention for oral leukoplakia
AU - Nagao, Toru
AU - Warnakulasuriya, Saman
AU - Sakuma, Hidenori
AU - Miyabe, Satoru
AU - Hasegawa, Shogo
AU - Machida, Junichiro
AU - Suzuki, Koji
AU - Fukano, Hideo
AU - Shimozato, Kazuo
AU - Hashimoto, Shuji
PY - 2017/5
Y1 - 2017/5
N2 - Background: We performed a randomized controlled chemoprevention trial of oral leukoplakia by administrating a low dose of beta-carotene and vitamin C supplements. 17% of subjects in the experimental arm (4/23) demonstrated clinical remission (complete or partial response) at completion of the trial. The objective of this study was to determine whether baseline expression of p53 and ki67 demonstrated any differences between those responding or not responding to our intervention. A secondary objective was to elucidate any relationship between dietary factors and clinical responses. Methods: For this biomarker study, we included all subjects in the experimental group (n = 23) who were non-smokers. Among 16 who completed the trial for 1 year of supplementation, there were four responders and 12 non-responders at 1-year follow-up. Following immuno-staining for p53 and ki67, the percentage of positive cell nuclei were analyzed as labeling index (LI). Results: Expression of p53 was greater in basal layers than in para-basal layers. Mean para-basal LI of p53 was higher in non-responding (26.0) than in responding subjects (11.2) (P = 0.028). ki67 LIs were not significantly different in the two groups. Conclusions: Expression of p53 was inversely related to clinical response to the supplements. Other biomarkers that may recognize subject's responsiveness to chemoprevention require further study.
AB - Background: We performed a randomized controlled chemoprevention trial of oral leukoplakia by administrating a low dose of beta-carotene and vitamin C supplements. 17% of subjects in the experimental arm (4/23) demonstrated clinical remission (complete or partial response) at completion of the trial. The objective of this study was to determine whether baseline expression of p53 and ki67 demonstrated any differences between those responding or not responding to our intervention. A secondary objective was to elucidate any relationship between dietary factors and clinical responses. Methods: For this biomarker study, we included all subjects in the experimental group (n = 23) who were non-smokers. Among 16 who completed the trial for 1 year of supplementation, there were four responders and 12 non-responders at 1-year follow-up. Following immuno-staining for p53 and ki67, the percentage of positive cell nuclei were analyzed as labeling index (LI). Results: Expression of p53 was greater in basal layers than in para-basal layers. Mean para-basal LI of p53 was higher in non-responding (26.0) than in responding subjects (11.2) (P = 0.028). ki67 LIs were not significantly different in the two groups. Conclusions: Expression of p53 was inversely related to clinical response to the supplements. Other biomarkers that may recognize subject's responsiveness to chemoprevention require further study.
UR - http://www.scopus.com/inward/record.url?scp=85018688711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018688711&partnerID=8YFLogxK
U2 - 10.1111/jop.12498
DO - 10.1111/jop.12498
M3 - Article
C2 - 27605086
AN - SCOPUS:85018688711
VL - 46
SP - 346
EP - 352
JO - Journal of Oral Pathology and Medicine
JF - Journal of Oral Pathology and Medicine
SN - 0904-2512
IS - 5
ER -